These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11434754)

  • 21. Herbal kava: reports of liver toxicity.
    Wooltorton E
    CMAJ; 2002 Mar; 166(6):777. PubMed ID: 11944767
    [No Abstract]   [Full Text] [Related]  

  • 22. Relevant hepatotoxic effects of kava still need to be proven. A statement of the Society for Medicinal Plant Research.
    Society for Medicinal Plant Research
    Planta Med; 2003 Nov; 69(11):971-2. PubMed ID: 14735431
    [No Abstract]   [Full Text] [Related]  

  • 23. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases.
    Teschke R; Schwarzenboeck A; Hennermann KH
    Eur J Gastroenterol Hepatol; 2008 Dec; 20(12):1182-93. PubMed ID: 18989142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis, in vitro, reactivity, and identification of 6-phenyl-3-hexen-2-one in human urine after kava-kava (Piper methysticum) ingestion.
    Zou L; Harkey MR; Henderson GL
    Planta Med; 2005 Feb; 71(2):142-6. PubMed ID: 15729622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kava: a test case for Canada's new approach to natural health products.
    Boon HS; Wong AH
    CMAJ; 2003 Nov; 169(11):1163-4. PubMed ID: 14638650
    [No Abstract]   [Full Text] [Related]  

  • 26. From the Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products--United States, Germany, and Switzerland, 1999-2002.
    JAMA; 2003 Jan; 289(1):36-7. PubMed ID: 12515265
    [No Abstract]   [Full Text] [Related]  

  • 27. Herbal hepatotoxicity: analysis of cases with initially reported positive re-exposure tests.
    Teschke R; Genthner A; Wolff A; Frenzel C; Schulze J; Eickhoff A
    Dig Liver Dis; 2014 Mar; 46(3):264-9. PubMed ID: 24315480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kava hepatotoxicity: a European view.
    Teschke R; Schwarzenboeck A; Akinci A
    N Z Med J; 2008 Oct; 121(1283):90-8. PubMed ID: 18841189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of kava hepatotoxicity and the FDA consumer advisory.
    Teschke R; Schulze J
    JAMA; 2010 Nov; 304(19):2174-5. PubMed ID: 21081732
    [No Abstract]   [Full Text] [Related]  

  • 30. Hepatic toxicity possibly associated with kava-containing products--United States, Germany, and Switzerland, 1999-2002.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(47):1065-7. PubMed ID: 12500906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited.
    Teschke R; Sarris J; Schweitzer I
    Br J Clin Pharmacol; 2012 Feb; 73(2):170-4. PubMed ID: 21801196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kava Hepatotoxicity: Are we any closer to the truth?
    Anke J; Ramzan I
    Planta Med; 2004 Mar; 70(3):193-6. PubMed ID: 15114493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Acute hepatitis due to kava-kava and St John's Wort: an immune-mediated mechanism?].
    Musch E; Chrissafidou A; Malek M
    Dtsch Med Wochenschr; 2006 May; 131(21):1214-7. PubMed ID: 16721710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulatory causality evaluation methods applied in kava hepatotoxicity: are they appropriate?
    Teschke R; Wolff A
    Regul Toxicol Pharmacol; 2011 Feb; 59(1):1-7. PubMed ID: 20854865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kava hepatotoxicity solution: A six-point plan for new kava standardization.
    Teschke R; Sarris J; Lebot V
    Phytomedicine; 2011 Jan; 18(2-3):96-103. PubMed ID: 21112196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxic hepatitis after consumption of traditional kava preparation.
    Christl SU; Seifert A; Seeler D
    J Travel Med; 2009; 16(1):55-6. PubMed ID: 19192130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of federal safety advisories on health food store advice.
    Mills E; Singh R; Ross C; Ernst E; Wilson K
    J Gen Intern Med; 2004 Mar; 19(3):269-72. PubMed ID: 15009783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are kavalactones the hepatotoxic principle of kava extracts? The pitfalls of the glutathione theory.
    Schmidt M
    J Altern Complement Med; 2003 Apr; 9(2):183-7; author reply 187-8. PubMed ID: 12804070
    [No Abstract]   [Full Text] [Related]  

  • 39. [Protective effect of dahuang zhechong pills on experimental hepatic injury].
    Qiu PL; Yuan SF; Shu CJ
    Zhong Xi Yi Jie He Za Zhi; 1988 Nov; 8(11):668-70, 646. PubMed ID: 3250764
    [No Abstract]   [Full Text] [Related]  

  • 40. Kava and severe liver injury.
    FDA Consum; 2002; 36(3):4. PubMed ID: 12085813
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.